Suven Pharmaceuticals rose 1.94% to Rs 569.35 after the company's consolidated net profit rose 40.87% to Rs 160.06 crore on 42.43% rise in net sales to Rs 391.58 crore in Q3 December 2021 over Q3 December 2020.
Profit before tax rose 62.35% to Rs 239.45 crore in Q3 December 2021 as against Rs 147.49 crore in Q3 December 2020.Total expenses jumped 46.23% to Rs 216.81 crore with cost of materials consumed soaring 48.55% to Rs 118.47 crore during the period under review.
The board has declared an interim dividend of Re 1 per equity share and one-time special dividend of Rs 2 per equity share for the financial year 2021-22. Record date is on 16 February 2022.
The board in its meeting held on 8th February 2022, has given its in-principle approval to evaluate the acquisition opportunity of Caper Pharma, an SEZ unit in Hyderabad engaged in formulations. The company will evaluate the proposal subject to financial, tax and legal due diligence to finalize the definitive agreements.
Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of global pharma industry.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU